BMS Jun 18, 2020 ArcherDx, Bristol Myers Squibb Partner on Minimal Residual Disease Monitoring May 18, 2020 Agilent PD-L1 Assay Gets FDA Approval as Metastatic NSCLC Companion Diagnostic Mar 4, 2020 Pulmonary Fibrosis Foundation, Celgene Form Biomarker Consortium Nov 12, 2019 Bristol-Myers, PathAI Show Artificial Intelligence Is on Par With Manual PD-L1 Scoring Premium Nov 5, 2019 PathAI Adds to Series B Round With Additional $15M Investment Mar 12, 2019 Biocartis Inks Cancer CDx Deal With Bristol-Myers Squibb Oct 9, 2018 PGDx Liquid Biopsy Assay to be Used in Cancer Drug Study Sep 13, 2018 Bristol-Myers Squibb to Use Natera's Cell-Free DNA Assay in Immunotherapy Study Apr 17, 2018 At AACR, Immuno-Oncology Clinical Trials Offer Mixed Messages on Predictive Biomarkers Premium Apr 13, 2018 Illumina, Bristol-Myers Squibb Partner on Companion Dx Development for Immunotherapy Feb 28, 2018 As Cancer Immunotherapy Evolves, Challenges Compound for Diagnostic Development Premium Feb 9, 2018 BMS Immunotherapy Combo Study Backs FoundationOne CDx Tumor Mutational Burden Indication Premium Sep 19, 2017 FDA Approves Agilent Complementary Dx for Two Additional Indications Apr 17, 2017 Bristol-Myers Squibb, Nordic Bioscience Collaborate on Nonalcoholic Fatty Liver Disease Biomarkers Jan 24, 2017 Outgoing FDA Commissioner, Pharma, Investors Discuss Regulation at Personalized Medicine Meeting Premium Sep 12, 2016 Opdivo Setback May Yield Lessons for Pharma Advancing Immunotherapies With PD-L1 Testing Premium Breaking News European Commission Outlines Intended Restorative Measures for Blocked Illumina-Grail Deal AnPac Bio to Raise $5M in Private Placement Top Five Articles on 360Dx Last Week: Sherlock Bio's $2M Award; Nostics' POC Testing Plans; and More KSL Pulse Scientific to Distribute Lucira Health Home COVID-19, Flu Molecular Test in Canada In Brief This Week: Chembio Diagnostics, Thermo Fisher Scientific, Renalytix, Theralink, More BTIG Downgrades Oncocyte to Neutral Following News of CEO Departure
